Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• T-cell-based immunotherapies like CAR-T cells and bispecific T-cell engagers (BiTEs) show promise but have limitations.
• These limitations include poor pharmacokinetics, single-antigen targeting, and the development of antigen-less tumor escape in multiclonal diseases.

Purpose of the Study:

• To develop novel nanoparticle-based immuno-engaging technologies to address current immunotherapy limitations.
• To create nanoparticle-based bispecific T-cell engagers (nanoBiTEs) and multi-antigen targeting nanoMuTEs.

Main Methods:

• Liposomes were decorated with anti-CD3 monoclonal antibodies (mAbs) for T-cell engagement and cancer antigen-targeting mAbs.
• NanoBiTEs target a single cancer antigen, while nanoMuTEs target multiple cancer antigens via conjugated mAbs.
• In vitro and in vivo efficacy, pharmacokinetics, and antigen-loss escape were evaluated.

Main Results:

• NanoBiTEs and nanoMuTEs exhibited a long half-life (~60 hours), allowing for weekly administration.
• NanoMuTEs demonstrated superior efficacy against myeloma cells compared to nanoBiTEs.
• NanoMuTEs prevented antigen-less tumor escape, unlike nanoBiTEs which showed antigen downregulation.

Conclusions:

• Nanoparticle-based immuno-engaging technology offers a solution to major limitations of current T-cell-based immunotherapies.
• NanoMuTEs represent a promising strategy for overcoming tumor escape and improving treatment outcomes in multiclonal cancers.